Skip to main content
Clinical Trials/ACTRN12623000133639
ACTRN12623000133639
Not yet recruiting
Phase 4

Continuous infusion of remimazolam for intraoperative sedation as a safe and effective option: a prospective clinical study.

Antonia Kustura, MD0 sites50 target enrollmentFebruary 8, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Procedural or intraoperative sedation.
Sponsor
Antonia Kustura, MD
Enrollment
50
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 8, 2023
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Antonia Kustura, MD

Eligibility Criteria

Inclusion Criteria

  • Adult patients between 18 and 80 years of age, ASA class I, II and III, scheduled for elective procedural sedation or sedation with regional anaesthesia.

Exclusion Criteria

  • Exclusion criteria are age under 18 or over 80, allergy to any of the drugs used, body mass index (BMI) under 18 or over 30, patients with psychiatric diagnoses, and patient refusal.

Outcomes

Primary Outcomes

Not specified

Similar Trials